Melane Sampson, Author at BioTuesdays

Executive Moves

Leone Patterson joins Kalaris as BOD chair of audit committee

Kalaris Therapeutics (NASDAQ:KLRS) announced the appointment of Leone Patterson to its board of directors (BOD) as chair of the audit committee. Ms. Patterson brings extensive experience as a biotech executive and board...

April 4, 2025

Developments

TrillaMed and Profound partner to bring TULSA-PRO to Veterans and service members

Profound Medical (NASDAQ:PROF; TSX:PRN) and TrillaMed, a Service-Disabled Veteran-Owned Business (SDVOSB), have announced a partnership to support the federal deployment of TULSA-PRO—the MRI-guided, incision-free...

April 4, 2025

Developments

AC Immune reveals positive Phase 2 data from trial in early PD

AC Immune (NASDAQ:ACIU) announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn trial evaluating ACI-7104.056—its anti-alpha-synuclein (a-syn) active immunotherapy candidate—for the...

April 3, 2025

Executive Moves

Laurie Glimcher joins ReAlta’s BOD

Closely held ReAlta Life Sciences has appointed immunologist Laurie Glimcher, MD, to its board of directors (BOD), effective immediately. Dr. Glimcher, widely renown for her work in cancer research, brings more than 35...

April 1, 2025

Feature

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

MaaT Pharma (EURONEXT:MAAT) is at the forefront of developing the world’s first full-ecosystem approach to restoring microbiome symbiosis in oncology, improving cancer patient survival through innovative, fecal-derived...

April 1, 2025

Developments

Kazia agrees to sell Cantrixil IP and trademark rights to Vivesto

Kazia Therapeutics (NASDAQ:KZIA) announced it will receive $1 million for the sale of all intellectual property (IP) and trademark rights of Cantrixil to Vivesto (Nasdaq Stockholm:VIVE). Vivesto licensed the exclusive...

March 31, 2025

Developments

Neural shares commence trading on Frankfurt Stock Exchange

Neural Therapeutics (CSE:NURL) announced that shares of the company have commenced trading on the Frankfurt Stock Exchange under symbol “M6B”. The company is developing therapeutics to address mental illnesses related...

March 31, 2025

Developments

Leap reports positive Phase 2 data of sirexatamab in MSS CRC

Leap Therapeutics (NASDAQ:LPTX) announced positive updated data from its Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy, compared to bevacizumab...

March 26, 2025

Developments

Coya reports progress of first-in-class Treg-derived exosome program

Coya Therapeutics (NASDAQ:COYA) announced a status update of its investigational regulatory T cell-derived exosome—Treg exosomes—platform for the treatment of systemic and neurodegenerative diseases driven by chronic...

March 26, 2025

Developments

Sunshine enters agreement to market generic antibiotics in Canada

Sunshine Biopharma (NASDAQ:SBFM) announced that it has signed an agreement to market two new generic antibiotics in Canada through its wholly owned Canadian subsidiary, Nora Pharma, subject to regulatory approval...

March 25, 2025

Author - Melane Sampson

Leone Patterson joins Kalaris as BOD chair of audit committee

TrillaMed and Profound partner to bring TULSA-PRO to Veterans and service members

AC Immune reveals positive Phase 2 data from trial in early PD

Laurie Glimcher joins ReAlta’s BOD

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

Kazia agrees to sell Cantrixil IP and trademark rights to Vivesto

Neural shares commence trading on Frankfurt Stock Exchange

Leap reports positive Phase 2 data of sirexatamab in MSS CRC

Coya reports progress of first-in-class Treg-derived exosome program

Sunshine enters agreement to market generic antibiotics in Canada

Subscribe